Results 181 to 190 of about 24,273 (376)

Dihydroxyphenylalanine and Hydroxytyramine in Mammalian Suprarenals. [PDF]

open access: yesActa Chemica Scandinavica, 1950
McC. Goodall   +3 more
openaire   +2 more sources

Distinct Longitudinal Clinical‐Neuroanatomical Trajectories in Parkinson's Disease Clinical Subtypes: Insight toward Precision Medicine

open access: yesMovement Disorders, EarlyView.
ABSTRACT Background Parkinson's disease (PD) varies widely across individuals in clinical manifestations and course of progression. Identification of distinct biological subtypes could explain this heterogeneity, identify its pathophysiology, and predict disease progression. Objectives Our aim was to compare longitudinal clinical trajectories and brain
Seyed‐Mohammad Fereshtehnejad   +7 more
wiley   +1 more source

L‐tyrosine and L‐dihydroxyphenylalanine as hormone‐like regulators of melanocyte functions

open access: yesPigment Cell & Melanoma Research, 2012
A. Slominski, M. Żmijewski, J. Pawelek
semanticscholar   +1 more source

The Changing Face of Dystonia—Enhancing Diagnosis by Moving Beyond Traditional Clinical Phenotyping

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Niroshan Jeyakumar, Kishore R. Kumar
wiley   +1 more source

Early‐Onset Movement Disorder Syndrome Caused by Biallelic Variants in PDE1B Encoding Phosphodiesterase 1B

open access: yesMovement Disorders, EarlyView.
Abstract Background Breakdown of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in basal ganglia cells through hydrolysis of diesteric bonds, primarily by PDE10A and PDE1B, is essential for normal human movement. While biallelic loss‐of‐function variants in PDE10A are known to cause hyperkinetic movement disorders, the ...
Tomer Poleg   +21 more
wiley   +1 more source

Early Levodopa Therapy in Tyrosine Hydroxylase Deficiency

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Claudio M. de Gusmao   +4 more
wiley   +1 more source

Disease‐Modifying Trials in Treated Parkinson's Disease: “Stable Treated” Does Not Equate with Biological Stability

open access: yesMovement Disorders, EarlyView.
Abstract Traditionally, clinical trials of putative disease‐modifying therapies in Parkinson's disease have enrolled untreated patients at the earliest clinical stages of their disease. Due to a number of challenges inherent with this approach, there has been a recent move to a different study design, enrolling patients who are already taking “stable ...
M. Maral Mouradian   +2 more
wiley   +1 more source

Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia

open access: yesNeurobiology of Disease, 2014
A role for enhanced peptidergic transmission, either opioidergic or not, has been proposed for the generation of l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia (LID) on the basis of in situ hybridization studies showing that striatal ...
Mathieu Bourdenx   +7 more
doaj  

Home - About - Disclaimer - Privacy